Glucagon like peptide-1 (GLP-1) agonists is the agonists of the GLP-1 receptor. This class of drugs is used for the treatment of type 2 diabetes. One of their advantages is over older insulin secretagogues, such as sulfonylureas or meglitinides, and they have a lower risk of causing hypoglycemia.
United States is the largest consumer of Glucagon like peptide-1 (GLP-1) agonists with the production market share of 35% and the consumption market share of 44% in 2015.

Market Analysis and Insights: Global Glucagon Like Peptide-1 (GLP-1) Agonists Market
The global Glucagon Like Peptide-1 (GLP-1) Agonists market size is projected to reach US$ 16460 million by 2026, from US$ 7781.9 million in 2020, at a CAGR of 13.3% during 2021-2026.

Global Glucagon Like Peptide-1 (GLP-1) Agonists Scope and Market Size
The global Glucagon Like Peptide-1 (GLP-1) Agonists market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Glucagon Like Peptide-1 (GLP-1) Agonists market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by region (country), by Type and by Application for the period 2015-2026.

Segment by Type, the Glucagon Like Peptide-1 (GLP-1) Agonists market is segmented into
Exenatied
Liraglutide
Lixisenatide
Albiglutide
Dulaglutide

Segment by Application, the Glucagon Like Peptide-1 (GLP-1) Agonists market is segmented into
Hospital
Pharmacy
Other

The Glucagon Like Peptide-1 (GLP-1) Agonists market is analysed and market size information is provided by regions (countries). Segment by Application, the Glucagon Like Peptide-1 (GLP-1) Agonists market is segmented into United States, Europe, China, Japan, Southeast Asia, India and Rest of World.
The report includes region-wise market size for the period 2015-2026. It also includes market size and forecast by players, by Type, and by Application segment in terms of sales and revenue for the period 2015-2026.

Competitive Landscape

and Glucagon Like Peptide-1 (GLP-1) Agonists Market Share Analysis
Glucagon Like Peptide-1 (GLP-1) Agonists market competitive landscape provides details and data information by players. The report offers comprehensive analysis and accurate statistics on revenue by the player for the period 2015-2020. It also offers detailed analysis supported by reliable statistics on revenue (global and regional level) by players for the period 2015-2020. Details included are company description, major business, company total revenue and the sales, revenue generated in Glucagon Like Peptide-1 (GLP-1) Agonists business, the date to enter into the Glucagon Like Peptide-1 (GLP-1) Agonists market, Glucagon Like Peptide-1 (GLP-1) Agonists product introduction, recent developments, etc.

The major vendors covered:
Novo Nordisk
AstraZeneca
Eli Lilly
GSK
Sanofi
Bristol-Myers Squibb
Amylin